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OBJECTIVE — To examine the sensitivity and speciﬁcity of A1C as a diagnostic test for type
2 diabetes in older adults.
RESEARCH DESIGN AND METHODS — Cross-sectional study of community-
dwelling adults without known diabetes who had an oral glucose tolerance test and A1C mea-
sured on the same day.
RESULTS — Meanageofthe2,107participantswas69.411.1years;43%weremen.Based
on the American Diabetes Association (ADA) criteria, 198 had previously undiagnosed type 2
diabetes. The sensitivity/speciﬁcity of A1C cut point of 6.5% was 44/79%. Results were similar
in age- and sex-stratiﬁed analyses. Given the A1C cut point of 6.5%, 85% of participants were
classiﬁed as nondiabetic by ADA criteria.
CONCLUSIONS — ThelimitedsensitivityoftheA1Ctestmayresultindelayeddiagnosisof
type 2 diabetes, while the strict use of ADA criteria may fail to identify a high proportion of
individuals with diabetes by A1C 6.5% or retinopathy.
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T
he current criteria for a diagnosis
of type 2 diabetes (1) require a
fasting plasma glucose (FPG) test
and/or a 75-g oral glucose tolerance test
(OGTT), a diagnostic method that is
time-consuming, requires fasting, and
isaffectedbyacuteperturbationsinglu-
cose levels and short-term lifestyle
changes.Eventhoughthetimeforonset
has been shortened in the last decades,
the onset of type 2 diabetes occurs years
before clinical diagnosis (2,3).
A1C has been suggested as a useful
tool for type 2 diabetes screening and di-
agnosis (4–6); it does not require fasting,
reﬂects the usual 3–4 months prior gly-
cemia, has less intraindividual variability,
and may better predict diabetes-related
complications (7,8). Recent reports have
stated that the cut point of 6.5% would
be diagnostic if conﬁrmed by a repeated
test (4,5). Further investigation of A1C
diagnostic performance in speciﬁc age
and sex groups is still lacking.
We designed the present study to de-
termine the sensitivity and speciﬁcity of
A1C for type 2 diabetes diagnosis com-
pared with the current OGTT gold stan-
dard as well as diabetic retinopathy (DR)
in a cohort of older adults from the Ran-
cho Bernardo Study.
RESEARCH DESIGN AND
METHODS— Participants included
2,107 adults without known type 2 dia-
betes or anemia who had an OGTT and
A1C test between 1984 and 1987. Glu-
cose tolerance status was deﬁned by the
American Diabetes Association (ADA)
OGTT criteria as 1) normoglycemia, FPG
100 mg/dl and 2-h postchallenge
glucose 140 mg/dl; 2) pre-diabetes,
FPG 100 mg/dl and 126 mg/dl or 2-h
postchallenge glucose 140 mg/dl and
200 mg/dl; and 3) type 2 diabetes, FPG
126mg/dlor2-hpostchallengeglucose
200 mg/dl (1). Anemia was assessed by
history.
All participants provided written in-
formed consent. The study protocol was
approved by the University of California,
San Diego Human Research Protection
Program.
Laboratory and anthropometric data
were performed as previously described
(9). A1C was measured with high-
performance liquid chromatography us-
ing an automated analyzer (normal range
4.5–6.5%) (SmithKline, Van Nuys, CA).
Ophthalmologic evaluation was per-
formed by nonmydriatic retinal photog-
raphy (10).
All analyses were performed using
SPSS version 13.1 (SPSS, Chicago, IL).
Receiver operating characteristic curves
were constructed to calculate sensitivity/
speciﬁcity of A1C cut points for type 2
diabetes diagnosis, and  coefﬁcients
were used to test for agreement between
A1C values and diabetes status.
RESULTS— Mean age was 69.4 
11.1 years; 43% were men. There were
198 participants with previously undiag-
nosed diabetes who had type 2 diabetes
by ADA criteria. At the time of diabetes
diagnosis, mean A1C was 6.5  1.07%
compared with 5.9  0.73% and 6.06 
0.75% in participants with normal glu-
cose and pre-diabetes, respectively (P 
0.001).
Overall, the A1C cut point of 6.5%
had a sensitivity/speciﬁcity of 44/79%
(area under receiver operating character-
istic curve 0.65) (Fig. 1A). The A1C cut
point of 6.15% yielded the highest com-
binationofsensitivity(63%)andspeciﬁc-
ity (60%) but would miss one-third of
thosewithtype2diabetesbyADAcriteria
and misclassify one-third of those with-
out. Results in sex-stratiﬁed analysis were
similar (Fig. 1B). In analysis stratiﬁed by
quartiles of age, the sensitivity/speciﬁcity
of A1C cut point of 6.5% was up to 52/
95% (Fig. 1C).
Using the A1C cut point of 6.5%, the
agreement with type 2 diabetes diagnosis
waslow(thecoefﬁcientwas0.119),and
85% of participants with A1C 6.5%
were classiﬁed as non-type 2 diabetes by
OGTT ADA criteria of whom 34% were
normoglycemic. When compared with
type 2 diabetes diagnosis based only on
FPG 126 mg/dl, the agreement was also
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tern was observed considering type 2 di-
abetes diagnosis based only on
postchallenge glucose 200 mg/dl ( co-
efﬁcient 0.112).
In order to compare A1C and ADA
criteria with a type 2 diabetes complica-
tion, we considered their prevalent reti-
nopathy. Only 1.8% (n  38) of these
individuals without known diabetes had
any degree of DR; of those, 40% had A1C
6.5% and none had type 2 diabetes by
ADA criteria.
CONCLUSIONS — In this cohort of
older adults, the suggested A1C cut point
of 6.5% had relatively low sensitivity and
speciﬁcity for type 2 diabetes diagnosis in
all age-groups and in both sexes. There
was low agreement between type 2 diabe-
tes diagnosis made by A1C and ADA cri-
teria. However, A1C criteria were met in
40% of the participants with prevalent
DR, while OGTT criteria were met in
none.
In a recent systematic review of nine
studies,Bennettetal.(5)reportedthatthe
A1Ccutpointof6.1%hadsensitivityof
78–91%andspeciﬁcityof79–84%com-
pared with OGTT. In contrast, data from
the National Health and Nutrition Exam-
inationSurvey(NHANESIII)showedthat
A1C 6.5% had sensitivity/speciﬁcity of
44/99% (11). The present study showed
sensitivity similar to that in the NHANES
reports; however, our speciﬁcity of 79%
for A1C 6.5% was much lower than
previouslyreported.Thisislikelybecause
these studies included much younger
populations.
The recently published International
Expert Committee Report on the role of
A1C for type 2 diabetes diagnosis (6)
states that there is no single assay for hy-
perglycemia that can be considered the
gold standard. In the present study, 85%
ofparticipantswithA1C6.5%werenot
classiﬁed as diabetic by ADA criteria and
one-thirdoftheparticipantswithdiabetes
by ADA criteria would be classiﬁed as
normoglycemic by A1C, i.e., a signiﬁcant
proportionofmisclassiﬁcation.Theseob-
servations raise two concerns: it would
not be desirable to miss those with high
A1C, considering that the burden of DR
correlates better with A1C than with FPG
or OGTT and that the prevalence of DR
increases substantially when A1C values
exceed 7% (6,8). On the other hand, per-
forming A1C instead of OGTT would
miss 30% of those who are already dia-
betic and those with pre-diabetes. Failing
to identify pre-diabetes would miss inter-
ventional opportunities to prevent or de-
lay type 2 diabetes (12).
To our knowledge, this is the ﬁrst re-
portofA1Cdiagnosticperformanceinthe
elderly. Our ﬁndings are important be-
cause the elderly in the U.S. have the
greatest current burden and are expected
to have the greatest increase in the preva-
lence of type 2 diabetes (13,14).
Weconcludethatthelimitedsensitiv-
ity of the A1C test may result in missed or
delayed diagnosis of type 2 diabetes,
whereas the use of current OGTT criteria
will fail to identify a high proportion of
individuals with A1C 6.5%. Further
studies and discussion are needed before
revising guidelines for type 2 diabetes
diagnosis.
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